Bank of America Securities Maintains a Neutral Stance on Pfizer Inc. (PFE)

Pfizer Inc. (NYSE:PFE) is one of the best large cap value stocks to buy now. On September 23, Bank of America Securities analyst Tim Anderson maintained a neutral stance on Pfizer Inc. (NYSE:PFE), giving the stock a Hold rating with a $28 price target.

Dividend Stock Portfolio for Retirement: Pfizer’s (PFE) Reliable Payouts

The analyst supported the rating with the company’s financial outlook and strategic moves, stating that Pfizer Inc.’s (NYSE:PFE) acquisition of Metsera is a notable and positive step in entering the obesity market.

However, Anderson added that the acquisition’s full potential is contingent on several pipeline-related milestones, and the deal is still subject to shareholder approval and other conditions.

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures in developing and emerging markets.

While we acknowledge the potential of PFE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PFE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.